We are live on
!
Find out more
DAWN
Day One Biopharmaceuticals
DAWN
DAWN
Delisted
DAWN was delisted on the 22nd of April, 2026.
172 hedge funds and large institutions have $603M invested in Day One Biopharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 54 increasing their positions, 61 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
more capital invested
Capital invested by funds: $ → $
less first-time investments, than exits
New positions opened: | Existing positions closed:
1% less funds holding
Funds holding: 174 → 172 (-2)
1.6% less ownership
Funds ownership: 85.16% → 83.57% (-1.6%)
11% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 61
Holders
172
Holding in Top 10
4
Calls
$641K
Puts
$432K
Top Buyers
| 1 | +$23.2M | |
| 2 | +$10.5M | |
| 3 | +$9.97M | |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$9.52M |
| 5 |
DM
Deerfield Management
New York
|
+$6.76M |
Top Sellers
| 1 | -$13.7M | |
| 2 | -$9.29M | |
| 3 | -$8.57M | |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.16M |
| 5 |
BlackRock
New York
|
-$5.7M |